Biohaven Taking Troriluzole Into Phase III OCD Study Despite Phase II/III Miss

 
• By Mandy Jackson

After a prior failure in treating anxiety, the company believes the glutamate modulator showed signs of efficacy in obsessive-compulsive disorder that are worth pursuing, including at a higher dose.

OCD Obsessive Compulsive Disorder written in notebook on white table
Troriluzole was numerically but not statistically better than placebo • Source: Shutterstock

More from Clinical Trials

More from R&D